Horm Metab Res 2015; 47(07): 485-490
DOI: 10.1055/s-0034-1395606
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Sex Hormone Binding Globulin and Risk of Breast Cancer in Postmenopausal Women: A Meta-Analysis of Prospective Studies

X. Y. He
1   Department of Oncology, People’s Hospital of Ganzhou, Ganzhou, China
,
Y. D. Liao
2   Department of Chemistry, Medical School of Ganzhou, Ganzhou, China
,
S. Yu
3   Department of Endocrinology, Affiliated Hospital of Qingdao University, Qingdao, China
,
Y. Zhang
4   Department of Oncology, Third Military Medical University, Chongqing, China
,
R. Wang
3   Department of Endocrinology, Affiliated Hospital of Qingdao University, Qingdao, China
› Author Affiliations
Further Information

Publication History

received 05 June 2014

accepted 03 November 2014

Publication Date:
07 January 2015 (online)

Abstract

Previous studies on the association between sex hormone binding globulin (SHBG) level and risk of breast cancer in postmenopausal women reported conflicting results. A meta-analysis of prospective studies was performed to evaluate the association between SHBG level and risk of breast cancer in postmenopausal women. Pubmed (1980 to July 2014) and EMBASE (1988 to July 2014) were searched for eligible studies. Eligible studies were prospective cohort or nested case-control studies on the association between SHBG level and risk of breast cancer in postmenopausal women. Meta-analysis using random-effects model was performed to calculate the pooled risk ratios (RRs) with 95% confidence intervals (95% CIs). Of 946 studies identified, 26 prospective studies from 21 publications were finally included in the meta-analysis. In postmenopausal women, the pooled RR for breast cancer comparing highest with lowest categories of SHBG was 0.64 (95% CI 0.57–0.72, p<0.001, I2=6.5%). The pooled RRs were not obviously altered in the sensitivity analyses and subgroup analyses. In cumulative meta-analysis, a more significant association between SHBG level and risk of breast cancer in postmenopausal women was observed as evidence accumulated by publication year. There was no obvious risk of publication bias. High SHBG level is significantly associated with decreased risk of breast cancer in postmenopausal women, and it’s a protective factor of breast cancer in postmenopausal women.

 
  • References

  • 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
  • 2 Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011; 378: 1461-1484
  • 3 De Bruijn KM, Arends LR, Hansen BE, Leeflang S, Ruiter R, van Eijck CH. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg 2013; 100: 1421-1429
  • 4 Gaudet MM, Gapstur SM, Sun J, Diver WR, Hannan LM, Thun MJ. Active smoking and breast cancer risk: original cohort data and meta-analysis. J Natl Cancer Inst 2013; 105: 515-525
  • 5 Heikkila K, Nyberg ST, Theorell T, Fransson EI, Alfredsson L, Bjorner JB, Bonenfant S, Borritz M, Bouillon K, Burr H, Dragano N, Geuskens GA, Goldberg M, Hamer M, Hooftman WE, Houtman IL, Joensuu M, Knutsson A, Koskenvuo M, Koskinen A, Kouvonen A, Madsen IE, Magnusson Hanson LL, Marmot MG, Nielsen ML, Nordin M, Oksanen T, Pentti J, Salo P, Rugulies R, Steptoe A, Suominen S, Vahtera J, Virtanen M, Vaananen A, Westerholm P, Westerlund H, Zins M, Ferrie JE, Singh-Manoux A, Batty GD, Kivimaki M. Work stress and risk of cancer: meta-analysis of 5 700 incident cancer events in 116 000 European men and women. BMJ 2013; 346: f165
  • 6 Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, Barricarte A, Berrino F, Krogh V, Sieri S, Brinton LA, Dorgan JF, Dossus L, Dowsett M, Eliassen AH, Fortner RT, Hankinson SE, Helzlsouer KJ, Hoff man-Bolton J, Comstock GW, Kaaks R, Kahle LL, Muti P, Overvad K, Peeters PH, Riboli E, Rinaldi S, Rollison DE, Stanczyk FZ, Trichopoulos D, Tworoger SS, Vineis P. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 2013; 14: 1009-1019
  • 7 Yang Z, Shen J, Cao Z, Wang B. Association between a novel polymorphism (rs2046210) of the 6q25.1 locus and breast cancer risk. Breast Cancer Res Treat 2013; 139: 267-275
  • 8 Fortunati N, Catalano MG. Sex hormone-binding globulin (SHBG) and estradiol cross-talk in breast cancer cells. Horm Metab Res 2006; 38: 236-240
  • 9 Rosner W, Hryb DJ, Kahn SM, Nakhla AM, Romas NA. Interactions of sex hormone-binding globulin with target cells. Mol Cell Endocrinol 2010; 316: 79-85
  • 10 Caldwell JD, Jirikowski GF. Sex hormone binding globulin and aging. Horm Metab Res 2009; 41: 173-182
  • 11 Avvakumov GV, Cherkasov A, Muller YA, Hammond GL. Structural analyses of sex hormone-binding globulin reveal novel ligands and function. Mol Cell Endocrinol 2010; 316: 13-23
  • 12 Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, Pisani P, Panico S, Secreto G. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996; 88: 291-296
  • 13 Dorgan JF, Longcope C, Stephenson Jr HE, Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA, Schatzkin A. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996; 5: 533-539
  • 14 Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606-616
  • 15 Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, Sieri S, Pala V, Berrino F. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004; 112: 312-318
  • 16 Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005; 12: 1071-1082
  • 17 Tworoger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA, Hankinson SE. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J Natl Cancer Inst 2005; 97: 595-602
  • 18 Zeleniuch-Jacquotte A, Gu Y, Shore RE, Koenig KL, Arslan AA, Kato I, Rinaldi S, Kaaks R, Toniolo P. Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. Int J Cancer 2005; 114: 323-327
  • 19 Woolcott CG, Shvetsov YB, Stanczyk FZ, Wilkens LR, White KK, Caberto C, Henderson BE, Le Marchand L, Kolonel LN, Goodman MT. Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study. Endocr Relat Cancer 2010; 17: 125-134
  • 20 Wurtz AM, Tjonneland A, Christensen J, Dragsted LO, Aarestrup J, Kyro C, Overvad K, Olsen A. Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy. Cancer Causes Control 2012; 23: 1711-1720
  • 21 Schoemaker MJ, Folkerd EJ, Jones ME, Rae M, Allen S, Ashworth A, Dowsett M, Swerdlow AJ. Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study. Br J Cancer 2014; 110: 1898-1907
  • 22 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
  • 23 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
  • 24 Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248-254
  • 25 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
  • 26 Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 1997; 76: 401-405
  • 27 Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 2000; 9: 575-579
  • 28 Buist DS, LaCroix AZ, Barlow WE, White E, Cauley JA, Bauer DC, Weiss NS. Bone mineral density and endogenous hormones and risk of breast cancer in postmenopausal women (United States). Cancer Causes Control 2001; 12: 213-222
  • 29 Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A, Lenner P. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control 2003; 14: 599-607
  • 30 Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004; 96: 1856-1865
  • 31 Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, Morris HA, Tilley WD, Giles GG. Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev 2010; 19: 492-502
  • 32 James RE, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjonneland A, Olsen A, Overvad K, Mesrine S, Engel P, Clavel-Chapelon F, Chang-Claude J, Vrieling A, Boeing H, Schutze M, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Krogh V, Panico S, Tumino R, Sacerdote C, Rodriguez L, Buckland G, Sanchez MJ, Amiano P, Ardanaz E, Bueno-de-Mesquita B, Ros MM, van Gils CH, Peeters PH, Khaw KT, Wareham N, Key TJ, Allen NE, Romieu I, Siddiq A, Cox D, Riboli E, Kaaks R. Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res (Phila) 2011; 4: 1626-1635
  • 33 Fourkala EO, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R, Soromani C, Hasenbrink G, Jacobs I, Dawnay A, Widschwendter M, Lichtenberg-Frate H, Menon U. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocr Relat Cancer 2012; 19: 137-147
  • 34 Sieri S, Muti P, Claudia A, Berrino F, Pala V, Grioni S, Abagnato CA, Blandino G, Contiero P, Schunemann HJ, Krogh V. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer 2012; 130: 921-929
  • 35 Farhat GN, Parimi N, Chlebowski RT, Manson JE, Anderson G, Huang AJ, Vittinghoff E, Lee JS, Lacroix AZ, Cauley JA, Jackson R, Grady D, Lane DS, Phillips L, Simon MS, Cummings SR. Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst 2013; 105: 1496-1503
  • 36 Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat 2013; 137: 883-892